Abstract
This article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines panel consisted of medical oncologists, pathologists, gastroenterologists, endocrinologists, and radiologists. The panel reviewed a series of questions regarding the medical management of patients with pancreatic neuroendocrine tumors as well as questions regarding surveillance after resection. The available literature was reviewed for each of the question and panel members voted on controversial topics, and the recommendations were included in a document circulated to all panel members for a final approval.
Author supplied keywords
- NANETS
- North American Neuroendocrine Tumor Society
- PRRT
- VIPoma
- capecitabine
- everolimus
- gastrinoma
- glucagonoma
- guidelines
- insulinoma
- islet cell tumors
- lanreotide
- octreotide
- pancreatic endocrine tumors
- pancreatic neuroendocrine carcinoma
- pancreatic neuroendocrine tumor
- peptide receptor radionuclide therapy
- somatostatin analogs
- somatostatinoma
- sunitinib
- temozolomide
Cite
CITATION STYLE
Halfdanarson, T. R., Strosberg, J. R., Tang, L., Bellizzi, A. M., Bergsland, E. K., O’Dorisio, T. M., … Chan, J. A. (2020, August 1). The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. Lippincott Williams and Wilkins. https://doi.org/10.1097/MPA.0000000000001597
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.